| INTRODUCTION

| Description of the condition
Oxygen therapy is used for all patients undergoing general anaesthesia. High inspiratory oxygen fractions (FiO 2 ) are often given before induction of general anaesthesia to achieve higher arterial oxygen concentration and, thus, have longer apnoea time as a safety precaution. Patients may commonly receive a FiO 2 of 1.00 for 3 minutes at the time of induction through a tightly sealed face mask.
1 A high FiO 2 may be continued throughout the anaesthesia on a level depending on the patient category and type of surgery. This is done to ensure sufficient oxygenation of vital organs such as the brain and heart. It is commonly accepted that while preoxygenation with 100%
oxygen is a safety precaution, it also has downsides: atelectasis occurs frequently and is correlated with the FiO 2 in such a way that preoxygenation with 80% oxygen leads to significantly less atelectasis than 100%, but also decreases the apnoea time before desaturation. 2 The target for intraoperative use of oxygen is currently not uniformly standardized. Many anaesthetists titrate FiO 2 to normoxia intraoperatively, whereas high-risk patients, such as patients with cardiovascular risk factors, commonly receive higher FiO 2 in an attempt to increase peripheral oxygen delivery to vulnerable organs. 3 In some circumstances, hyperoxia is deliberately chosen since it may have a beneficial effect on surgical site infection (SSI), because adequate oxygen delivery to the wound facilitates the bacterial killing by neutrophils. 4, 5 The effects of anaesthesia on vital organs, such as the heart, are still an area of extensive research. Myocardial injury in the post-operative setting is a relative common finding, but is often missed clinically because more than 60% of infarcted patients have no ischaemic symptoms. 6 Myocardial infarction was reported in 3.3% of patients in the POISE-2 trial, which included adult patients undergoing general anaesthesia who were expected to have at least one post-operative day of admittance. 7 The incidence of myocardial injury after non-cardiac surgery (MINS) was 4.6%, but the association between these post-operative complications and perioperative use of oxygen in these cases is not clearly determined.
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| Description of the intervention
Hyperoxia may cause adverse events due to increased oxidative stress. Reactive oxygen species (ROSs) are created in excess when arterial oxygen concentration reaches supranormal levels. ROSs are highly reactive with the surroundings, and ROSs also react with cellular lipids, forming lipid peroxides, which in excess leads to necrosis, untimely apoptosis, and may even play a role in carcinogenesis. [10] [11] [12] [13] In the heart, hyperoxia has been shown to reduce coronary artery blood flow through coronary vascular resistance, increase systemic vascular resistance and decrease cardiac index. [14] [15] [16] [17] [18] [19] Hyperoxia has also been associated with increased infarct size in patients with acute myocardial infarction, in-hospital mortality and pulmonary complications post-operatively. 8, 20, 21 A post hoc analysis from a large randomized clinical trial found perioperative hyperoxia to be associated with increased long-term mortality in patients undergoing abdominal surgery. 22 However, a 23 The Center of Disease Control and Prevention (CDC) followed in 2017 and recommend "increased FiO 2 during surgery and after extubation in the immediate post-operative period" to reduce surgical site infections. 24 Pulmonary complications were examined in the 2015 Cochrane review, but it did not evaluate the potential cardiac risks. 9 We have reason to believe that hyperoxia in the perioperative setting needs to be addressed because of studies that have examined the effects of hyperoxia on coronary arteries as well as hyperoxia in the medical setting of acute myocardial infarction and after cardiac arrest resuscitation. 20, 21 One way to discover myocardial injury is by measuring cardiac troponin, which is a strong and independent predictor of myocardial injury and death, and the measurement of troponin the first days after surgery can identify MINS. 25 Supplemental oxygen treatment has also been advised in acute medical settings, such as the initial treatment of acute coronary syndrome (ACS) where all patients with acute chest pain suspected of having ACS were administered supplemental oxygen irrespective of their oxygenation status. The newest guidelines have changed this due to studies that have challenged the safety of hyperoxia, now stating that "patients with acute chest pain with presumed ACS do not need supplemental oxygen unless they present with signs of hypoxia, dyspnoea, or heart failure." 26 The debate on the effects of hyperoxia on SSI is ongoing, partly because there is not adequate evidence on the benefit regarding SSI, and partly because we do not yet have enough evidence on the potential harms to make a recommendation in this regard.
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| Objective
The aim of this systematic review is to investigate the effect of a high FiO 2 (high = above 0.60 vs normal = below 0.40) on cardiac complications in patients undergoing non-cardiac surgery. We will relate the outcome of cardiac complications to the estimates of the primary outcomes of all-cause mortality and surgical site infections from the Cochrane review: The effects of high perioperative inspiratory oxygen fraction for adult surgical patients. The oxygen intervention must be given during surgery and may or may not be continued post-operatively. Trials will be included in meta-analyses if data are available for cardiac complications or biomarkers of myocardial injury. We will exclude pseudo-randomized trials (eg trials allocating participants due to equal or unequal dates). We will only include whole trials or trials having been stratified for our inclusion criteria. Timeframe is from 1946 until present.
All languages are considered as long as title and abstract are available in English.
| Participants
Trials including adult patients, as defined in the original trials, undergoing non-cardiac surgery in general or regional anaesthesia. 
| Information sources
We will search the following electronic databases:
1. MEDLINE
EMBASE
Cochrane CENTRAL
Web of Science
CINAHL
| Search and study selection
The search strategy for this review will be a slightly altered and updated version of the search strategy used in the Cochrane review "The effects of high perioperative inspiratory oxygen fraction for adult surgical patients."
9 Two authors will screen all titles and abstracts, and eligible trials will be reviewed in full text by 2 authors. Any cases of doubt will be settled between the 2 authors and conferred with a senior author in case of doubt.
Data on primary and secondary outcome will be extracted from the included trials using a data extraction form. In case of missing data on our primary outcome, we will contact the corresponding author of these studies to provide additional data. Authors will be contacted a second time after 14 days, if there has been no answer upon initial contact.
| RESULTS
| Primary outcome
1. Myocardial infarction, as defined by the author, at longest follow-up
| Secondary outcomes 1. MINS within 30 days
2. Non-fatal cardiac arrest at longest follow-up
New onset unstable angina at longest follow-up
We will describe other cardiac complications if they are reported in the article.
| GRADE and risk of bias assessment
The overall quality of evidence for each outcome will be assessed with the Grading of Recommendation, Assessment, Development and Evaluation (GRADE).
The quality of evidence will be assessed in accordance with the GRADE guidelines in 4 categories: High, Moderate, Low and Very low. 29 In this review, we only include randomized clinical trials, and as such, the quality of evidence will begin at "High." Downgrading will be done by assessing the risk of bias, inconsistency, indirectness, imprecision and publication bias. Upgrading will be done if assessed effect size is large, a clear dose-response documented, and if all would either reduce the documented effect or suggest a spurious effect if no effect is found.
We will assess the risk of bias in the domains of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other sources of bias. 30 We will define trials as having overall low risk of bias if they are judged as having low risk of bias on all examined domains of bias and as overall high risk of bias if one or more bias domains are judged to be high or uncertain risk of bias.
Two authors will assess the quality of evidence independently and disagreements will be consulted with a third author to reach consensus.
| Data analysis
The primary analysis of this review will be performed on trials with overall low risk of bias.
We will perform meta-analyses with random-effects or fixedeffects model as appropriate according to study heterogeneity. We anticipate the clinical heterogeneity to be high, and accordingly, we will stress the results from the random-effects model unless 1 or 2 trials dominate the number of randomized participants (say include more than 80% of the number of randomized participants) in which case we will emphasize the fixed-effects model if the point-estimate diverge substantially in the 2 models. 31 We will measure statistically heterogeneity by I 2 and consider it statistically significant when the P value is <.10. For dichotomous outcomes, risk ratio (RR) with 95% confidence interval (CI) will be reported, and for cardiac biomarkers, we will calculate standardized mean difference (SMD).
Our primary analysis is based on complete case analysis of trials reporting data on cardiac outcomes. If these trials have incomplete reporting of our primary or secondary outcome, we will perform a best case/worst case analysis. 
| Trial Sequential Analyses
There is a risk of producing random errors in meta-analyses, and to address this, we will conduct Trial Sequential Analyses (TSA). Random errors occur due to multiple testing of accumulating data and when data are sparse. 30, [33] [34] [35] [36] [37] [38] [39] The TSA gives an estimate of the required number of participants as well as a TSA-adjusted confidence intervals (CIs) which will enable us to detect or reject the intervention effect in the meta-analyses. [40] [41] [42] For estimation of the required information size, we will use a diversity-adjusted required sample size for an equally powered trial to detect a 20% relative risk reduction (RRR). 43, 44 To reduce the risk of random error, we will use conservative estimates of the anticipated intervention effects. 31 In brief, as we have 1 primary outcome and 3 secondary outcomes, we will consider a P < .05 and P < .025 as statistically significant, respectively, in order to limit the family wise error rate (FWER) to <0.05. 31, 45, 46 If there is only data available for 1 or 2 of the secondary outcomes, multiplicity adjustment will be corrected and we will consider a P < .05 or P < .033 as statistically significant, respectively. 31, 45, 46 In the TSA, we will use a RRR of 20% corresponding to a FWER equal to an alpha of 5% and a beta of 10%, giving it a power of 90% to detect a type 1 or type 2 error risk.
We will calculate the control event proportion (CEP) from the unweighted proportion of events in all trials.
| Additional analyses
Subgroup analysis will be performed according to:
1. Overall risk of bias: We will compare our primary analysis of trials with overall low risk of bias with an analysis of the subgroup of trials with overall uncertain or high risk of bias. We hypothesize that there will be less harm with hyperoxia in the trials of high risk of bias.
2.
Follow-up equal to or longer than 30 days. We hypothesize that there will be more harm with hyperoxia when the follow-up is longer due to the time frame for events being expanded.
3.
Trials using or not using N 2 O. We hypothesize that there will be less harm with hyperoxia in trials using N 2 O, due to the larger use of N 2 O in the control groups. N 2 O may potentially affect cardiovascular outcomes. 47, 48 4. Trials investigating patients in general anaesthesia or in regional anaesthesia. We hypothesize that there will be less harm with hyperoxia in the patients with regional anaesthesia due to the difficulty of maintaining a potentially harmful high FiO 2 of 0.80 when the patient is not intubated.
5.
Trials using a FiO 2 of 0.80 or higher in the intervention group compared with trials using an FiO 2 equal to or greater than 60% but lower than 80%. We hypothesize that there will be less harm with hyperoxia in the 60% group, due to less oxidative stress than in the 80% group.
We will also perform sensitivity analyses, in which we:
1. Exclude trials with patients without cardiac risk at baseline. We hypothesize that there will be more harm with hyperoxia because it has been shown to have negative effects in patients with STsegment-elevation myocardial infarction. 21 
| DISCUSSION
We have chosen a primary outcome of myocardial infarction because this is of the utmost interest due to the possible pathophysiological mechanisms induced by hyperoxia, and this outcome has not been investigated previously. We will not ignore conclusions on all-cause mortality drawn from the Cochrane review carried out on the hyperoxia effect on surgical site infections, but on the contrary, we will integrate the knowledge from the updated Cochrane review in the conclusions resulting from the present review.
The strengths of this review are the robust statistical analyses, that will be applied and that this review will adhere to standards and guidelines recommended for systematic reviews. A potential limitation of this review is the quality of studies included in the review, since all studies that fulfil the inclusion criteria, will be included.
However, we adjust for this by basing our conclusions primarily on meta-analysis from trials with overall low risk of bias and discuss the possible bias effect if detected in our planned subgroup analyses. If no bias effect is detected, we will acknowledge the possible narrower CIs from the analyses of all trials.
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